Farmas USA

BMY

issued a press release last night stating that it would not
pursue an accelerated regulatory submission for the combination of its two immunooncology
(IO) drugs, Yervoy and Opdivo, in first-line lung cancer. Non-small cell lung cancer
(NSCLC) is the largest potential indication for IO therapies and is a hotly contested space, so
even small changes to timelines attract scrutiny.

http://www.twitlonger.com/show/n_1spi0vu

Del Bastardo. Básicamente, que ha perdido su puesto de líder tras el ensayo de Opdivo end fármacos oncológicos.

https://www.thestreet.com/story/13960391/1/bristol-myers-squibb-where-art-thou-not-in-first-line-lung-cancer-immunotherapy-sadly.html

GILD

European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)

http://www.businesswire.com/news/home/20170120005204/en/European-Medicines-Agency-Validates-Gilead%E2%80%99s-Marketing-Authorization

PD: y ayer no me entró por 3 céntimos :(

PSTI

Para el 25 de enero

Pluristem Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000

http://globenewswire.com/news-release/2017/01/20/909621/0/en/Pluristem-Increases-Previously-Announced-Bought-Deal-Offering-of-Common-Stock-and-Warrants-to-15-000-000.html

ADXS
Vendidas las que me quedaban a 8,60. Lo he hecho fatal sin poder estar pendiente ayer.
KERX
Compradas a 5,45.

tgtx

si no hay soporte en estos niveles 4$

zona 3.20$

GILD

Dentro unas cuantas a 71,13

TGTX
El la acción de este stock, en modo selloff día tras día, hace pensar en el fallo de GENUINE...

AMGN , MACD diario en rojo ( a terminar de confirmar hoy ), la ultima vez que se puso en rojo rondaba los 175 en Agosto, ojo con eso.